TSH Biopharm Corporation Limited

TPEX:8432 Stock Report

Market Cap: NT$2.4b

TSH Biopharm Past Earnings Performance

Past criteria checks 5/6

TSH Biopharm has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 18.7% per year. TSH Biopharm's return on equity is 8.6%, and it has net margins of 11.4%.

Key information

2.5%

Earnings growth rate

2.5%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate18.7%
Return on equity8.6%
Net Margin11.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Feb 18
Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

Jan 21
Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Dec 16
TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Revenue & Expenses Breakdown

How TSH Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:8432 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,05112035625
30 Jun 249328833425
31 Mar 248679231025
31 Dec 238116231125
30 Sep 239835438736
30 Jun 238265535034
31 Mar 237655332333
31 Dec 227416229331
30 Sep 224506818014
30 Jun 224376017420
31 Mar 224325717121
31 Dec 214134716824
30 Sep 214314717232
30 Jun 214325317528
31 Mar 214184817729
31 Dec 204486218229
30 Sep 204425318932
30 Jun 204738319742
31 Mar 205038420547
31 Dec 195088520653
30 Sep 195028920059
30 Jun 194825218563
31 Mar 195035017891
31 Dec 185165817697
30 Sep 185216317397
30 Jun 1853673172100
31 Mar 185218517576
31 Dec 174866517274
30 Sep 174975817689
30 Jun 174754217989
31 Mar 1748598173110
31 Dec 16492141174116
30 Sep 16487165187121
30 Jun 16505176189120
31 Mar 16506127191106
31 Dec 1551483194106
30 Sep 155315919393
30 Jun 155465520199
31 Mar 155545921389
31 Dec 145627421386
30 Sep 145658119297
30 Jun 145829719693
31 Mar 1458510419493
31 Dec 1359711019587

Quality Earnings: 8432 has high quality earnings.

Growing Profit Margin: 8432's current net profit margins (11.4%) are higher than last year (5.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 8432's earnings have grown by 2.5% per year over the past 5 years.

Accelerating Growth: 8432's earnings growth over the past year (122.6%) exceeds its 5-year average (2.5% per year).

Earnings vs Industry: 8432 earnings growth over the past year (122.6%) exceeded the Pharmaceuticals industry 11.9%.

Return on Equity

High ROE: 8432's Return on Equity (8.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:18
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TSH Biopharm Corporation Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi-hsin LeeJih Sun Securities Investment Consulting Co., Ltd.
Hsiu Chi LinMasterlink Securities Corp.